Table 1.
Baseline characteristics and previous treatments in PS and PR patients.
| Overall | PS | PR | p | |
|---|---|---|---|---|
| n = 111 | n = 81 | n = 30 | ||
| Age at diagnosis (years), Median [IQR] | 59.8 [53.9; 69.4] |
60.0 [55.7; 69.2] |
58.1 [52.5; 70.3] |
0.725 |
| Histology, n (%): | 0.573 | |||
| HGSOC | 107 (96.4%) |
77 (95.1%) |
30 (100.0%) |
|
| HGEOC | 4 (3.6%) | 4 (4.9%) | 0 (0.0%) | |
| BRCA mutational status, n (%): | 0.131 | |||
| Positive | 46 (41.4%) |
36 (44.4%) |
10 (33.3%) |
|
| WT | 59 (53.2%) |
39 (48.1%) |
20 (66.7%) |
|
| Variants of unknown significance (VUS) | 6 (5.4%) | 6 (7.4%) | 0 (0.0%) | |
| Other HRR genes mut, n (%): | - | |||
| Positive | 9 (9.6%) | 8 (11.3%) |
1 (4.3%) | |
| Pt-based chemo immediately previous to PARPi, n (%): | 1.000 | |||
| Pt monotherapy | 11 (9.9%) | 8 (9.9%) | 3 (10.0%) | |
| Pt doublet | 100 (90.1%) |
73 (90.1%) |
27 (90.0%) |
|
| Months from last cycle of prior Pt to initiation of Pt immediately pre-PARPi (prior TFI), n (%): | 0.019 | |||
| <6 m | 3 (2.7%) | 0 (0.0%) | 3 * (10.0%) | |
| 6–12 m | 46 (41.4%) |
33 (40.7%) |
13 (43.3%) |
|
| >12 m | 58 (52.3%) |
46 (56.8%) |
12 (40.0%) |
|
| Non-available | 4 (3.6%) | 2 (2.5%) | 2 (6.7%) | |
| Number of previous lines to PARPi (including the immediately previous), Median [IQR] |
2.0 [2.0; 3.0] |
2.0 [2.0; 3.0] |
2.0 [2.0; 3.8] |
0.267 |
| Number of previous lines to PARPi (including the immediately previous), n (%): | 0.730 | |||
| =2 | 64 (57.7%) |
48 (59.3%) |
16 (53.3%) |
|
| >2 | 47 (42.3%) |
33 (40.7%) |
14 (46.7%) |
|
| Number of cycles of Pt-based chemo immediately previous to PARPi, Median [IQR] | 6.0 [5.0; 6.0] | 6.0 [5.0; 6.0] |
6.0 [5.0; 6.0] |
0.072 |
| Best response to Pt-based chemo immediately previous to PARPi, n (%): | 0.319 | |||
| CR | 21 (18.9%) |
18 (22.2%) |
3 (10.0%) | |
| PR | 81 (73.0%) |
57 (70.4%) |
24 (80.0%) |
|
| SD | 9 (8.1%) | 6 (7.4%) | 3 (10.0%) | |
| Months with Pt-based CT treatment, Median [IQR] | 4.3 [3.5; 5.1] | 4.6 [3.6; 5.5] |
4.1 [3.4; 4.7] |
0.055 |
| PARPi, n (%): | 0.008 | |||
| olaparib | 49 (44.1%) |
42 (51.9%) |
7 (23.3%) | |
| niraparib | 60 (54.1%) |
37 (45.7%) |
23 (76.7%) |
|
| rucaparib | 2 (1.8%) | 2 (2.5%) | 0 (0.0%) | |
| Months with PARPi, Median [IQR] | 7.4 [4.3; 12.2] |
9.5 [6.5; 14.7] |
3.7 [2.8; 4.0] |
<0.001 |
| Prior PARPi, n (%): | 0.388 | |||
| Yes | 1 (1.0%) | 1 (1.3%) | 0 (0.0%) | |
| No | 99 (96.1%) |
74 (97.4%) |
25 (92.6%) |
|
| Maybe | 3 (2.9%) | 1 (1.3%) | 2 (7.4%) | |
| Months from finishing Pt pre-PARPi to Pt pre-PARPi progression (PFI), Median [IQR] | 9.3 [5.6; 14.2] |
12.0 [8.8; 17.1] |
4.6 [3.7; 5.2] |
<0.001 |
| Months from PARPi initiation to Pt pre-PARPi progression (PFI-PARPi), Median [IQR] | 7.5 [4.0; 12.3] |
9.9 [6.2; 14.6] |
3.0 [2.4; 3.9] |
<0.001 |
Pt: platinum; PS: platinum-sensitive; PR: platinum-resistant. * in spite of prior TFI < 6 months, patient’s physician considered that these 3 patients would benefit from rechallenge with platinum at relapse and after this new platinum-based line they eventually prescribed PARPi as maintenance.